<DOC>
	<DOCNO>NCT01417676</DOCNO>
	<brief_summary>This prospective , open label 1 arm study , multicentre , Phase I/II clinical safety study . The trial design gain initial safety efficacy data pelvic lymph node radiation simultaneous integrate boost prostate high risk prostate cancer patient .</brief_summary>
	<brief_title>DAPROCA Pelvic Lymph Node Irradiation Prostate High Risk Prostate Cancer : Phase I/II Study</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>adenocarcinoma T3 tumor either Gleason 810 PSA ≤ 70 , PSA ≥ 30 PSA ≤ 70 , T1T3 PSA ≤ 70 N1 distant metastasis pelvic comorbidity Crohns disease ulcerative colitis uncontrolled heart lung morbidity prior radiation treatment pelvic region age &gt; 75 year</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>locally advanced</keyword>
	<keyword>lymph node positive</keyword>
	<keyword>radiation therapy</keyword>
	<keyword>morbidity</keyword>
	<keyword>early morbidity</keyword>
	<keyword>late morbidity</keyword>
</DOC>